Evaxion Stock Surges on 3-Year Melanoma Vaccine Trial Data

3-line summary

• Evaxion said all patients in a Phase 2 trial of its AI-designed personalized cancer vaccine EVX-01 for advanced melanoma maintained the clinical response seen at year two through the three-year follow-up mark, with no tumor progression observed; patients received EVX-01 as monotherapy in year three.
• At the two-year mark (presented at ESMO 2025), the trial showed a 75% objective response rate, 25% complete response, 92% durability of response, and no relapses after combining EVX-01 with Merck's Keytruda for the first two years; 6 of 12 responders entered a one-year extension on monotherapy. Additional two-year data showed 54% of patients had deepening responses after treatment, tumor shrinkage in 15 of 16 enrolled patients, and vaccine-specific T-cell responses against 86% of targeted neoantigens.
• Evaxion shares (EVAX) rose 21.6% Monday; the company plans to present the data at the ESMO Congress 2026 in Madrid (October 23-27) followed by a webinar on October 29.

This summary is our own processing of the source article; see the source link below for full context.